Livforsakringsbolaget Skandia Omsesidigt Buys 20,800 Shares of United Therapeutics Corporation $UTHR

Posted by Geri Gentry on Jun 5th, 2026

Livforsakringsbolaget Skandia Omsesidigt increased its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 5,200.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 21,200 shares of the biotechnology company’s stock after acquiring an additional 20,800 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in United Therapeutics were worth $10,320,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of UTHR. Torren Management LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC boosted its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $31,000. 94.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $547.87, for a total value of $5,478,700.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,341,594.12. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,185,323.93. This trade represents a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 614,043 shares of company stock worth $346,186,880. Company insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

UTHR opened at $547.69 on Friday. The firm’s fifty day moving average is $568.06 and its two-hundred day moving average is $518.61. The firm has a market cap of $23.25 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the business posted $6.63 earnings per share. Equities analysts forecast that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. Bank of America raised their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

View Our Latest Stock Analysis on United Therapeutics

United Therapeutics Company Profile

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.